WA-AUTH0
16.6.2021 15:04:04 CEST | Business Wire | Press release
Auth0 , the modern identity platform, today announced the launch of its inaugural security report: The State of Secure Identity . This detailed report highlights key areas of concern for security professionals responsible for managing digital identities, including the exponential rise of credential stuffing attacks (automated attempts to compromise a large number of user accounts with stolen credentials), fraudulent registrations, and the widespread use of breached credentials.
Recent headlines and high-profile cyber attacks give today’s security professionals a wide swath of serious threats to worry about. The primary goal of cybercriminal activity is to access critical resources, systems, and personal data, yet systems that can be put into place to minimize the risk of attack — like identity management — often get deprioritized. Lack of budget, resourcing, or attention on managing digital identities give threat actors a prime opportunity to take advantage of these discrepancies and surreptitiously execute their attacks.
Research into Auth0’s global customers over the past year found these key facts and figures:
- In the first 90 days of 2021, credential stuffing accounted for 16.5% of attempted login traffic on its platform, with a peak of over 40% near the end of March — all of which Auth0 detected and prevented.
- Travel & leisure and retail are the top two industries most affected by credential stuffing attacks.
- The number of fraudulent registrations vary by industry vertical, but roughly 15% of all attempts to register a new account can be attributed to bots.
- In the first 90 days of 2021, the Auth0 platform detected breached passwords at an average of more than 26,600 per day, with a minimum of just under 7,300 and a high on Feb. 9, 2021 exceeding 182,000.
“Securing customers’ identities is made more difficult by industry-wide failures to protect data. The prevalence of breached passwords and the availability of automated attack tools makes the humble password a protective measure from the past,” said Duncan Godfrey, VP of Security Engineering, Auth0. “The State of Secure Identity Report is designed to share our unique identity security insights and recommendations with the industry so that application builders and developers at any organization can take the steps they need to improve their overall security posture, and make things more secure for end users.”
The most prevalent threats detailed in the report include Credential Stuffing (the most common threat observed by Auth0); Fraudulent Registrations; Multi-factor Authentication Bypass; Breached Password Usage; and other common identity attacks. The complete Auth0 State of Secure Identity Report, which includes additional key findings and recommendations on how organizations can improve their identity security posture, can be downloaded here . Auth0 will also be hosting an online meetup to examine these insights in greater detail on Thursday June 24 at 8:00 AM PDT .
Auth0, recently acquired by Okta , provides a modern identity platform that helps organizations meet the security, privacy, and convenience needs of their users. Please visit the Auth0 identity OS to learn more.
About Auth0
Auth0’s modern approach to identity enables organizations to provide secure access to any application, for any user. The Auth0 platform is a highly customizable identity operating system that is as simple as development teams want and as flexible as they need. Safeguarding billions of login transactions each month, Auth0 delivers convenience, privacy, and security so customers can focus on innovation. For more information, visit https://auth0.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005028/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom